Low-level Bcr–Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib

✍ Scribed by Simona Soverini; Alessandra Gnani; Caterina De Benedittis; Fausto Castagnetti; Gabriele Gugliotta; Ilaria Iacobucci; Francesca Palandri; Gianantonio Rosti; Nicoletta Testoni; Simona Luatti; Giulia Marzocchi; Michele Baccarani; Giovanni Martinelli

• Book ID: 113773460
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 311 KB
• Volume: 35
• Category: Article
• ISSN: 0145-2126
• DOI: 10.1016/j.leukres.2011.05.029